Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:CYNA
CUSIPN/A
Phone+1-416-7032449
Debt
Debt-to-Equity Ratio0.05
Current Ratio4.45
Quick Ratio4.44
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-35.81%
Return on Assets-32.75%
Miscellaneous
Employees25
Outstanding Shares13,150,000
Cynapsus Therapeutics (NASDAQ:CYNA) Frequently Asked Questions
What is Cynapsus Therapeutics' stock symbol?
Cynapsus Therapeutics trades on the NASDAQ under the ticker symbol "CYNA."
How were Cynapsus Therapeutics' earnings last quarter?
Cynapsus Therapeutics Inc (NASDAQ:CYNA) released its earnings results on Wednesday, August, 10th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.77) by $0.06. View Cynapsus Therapeutics' Earnings History.
When did Cynapsus Therapeutics IPO?
(CYNA) raised $64 million in an IPO on Thursday, June 18th 2015. The company issued 4,500,000 shares at a price of $14.18 per share. BofA Merrill Lynch served as the underwriter for the IPO and Nomura and Noble Life Science Partners were co-managers.
Has Cynapsus Therapeutics been receiving favorable news coverage?
Media stories about CYNA stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cynapsus Therapeutics earned a news sentiment score of 0.22 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 43.66 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
How do I buy shares of Cynapsus Therapeutics?
Shares of CYNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cynapsus Therapeutics' stock price today?
One share of CYNA stock can currently be purchased for approximately $40.4805.
How can I contact Cynapsus Therapeutics?
Cynapsus Therapeutics' mailing address is 828 Richmond St W, TORONTO, ON M6J 1C9, Canada. The biotechnology company can be reached via phone at +1-416-7032449.
MarketBeat Community Rating for Cynapsus Therapeutics (CYNA)
MarketBeat's community ratings are surveys of what our community members think about Cynapsus Therapeutics and other stocks. Vote "Outperform" if you believe CYNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
